Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Hysolv UK launches new swine flu vaccination
The new vaccine protects against the pandemic strain of flu pdmH1N1.
Vaccine to be used in conjunction with Respiporc FLU3

A new swine flu vaccination has been launched by Hysolv Animal Health UK.

In a press release, Hysolv said the vaccine - Respiporc FLUpanH1N1 - protects against the pandemic strain of flu pdmH1N1, which is prevalent in the British Isles.

Two 1ml doses of the inactivated vaccine can be injected intramuscularly three weeks apart to pigs over the age of 56 days, providing immunisation to the majority of animals within seven days.

Developed by IDT Biologika, the vaccine has already proved a success in Germany, where 1.7 million doses have been prescribed. Field trials revealed that vaccination not only protected against clinical signs of influenza, it also resulted in improvements in reproduction and piglet performance.

Hysolv is strongly advising that Respiporc FLUpanH1N1 is used in conjunction with its existing vaccine, Respiporc FLU3. This is because Respiporc FLU3 gives protection against three other strains of swine flu (H1N1, H1N2 and H3N2).

‘When used together, the two vaccines protect pigs against the most relevant strains in the British Isles,” the company said. 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.